<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589222</url>
  </required_header>
  <id_info>
    <org_study_id>GEM- SELIBORDARA</org_study_id>
    <nct_id>NCT03589222</nct_id>
  </id_info>
  <brief_title>SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma</brief_title>
  <official_title>An Open-label, Multicenter, Phase 2 Trial of Selinexor (KPT-330), Bortezomib and Low-dose Dexamethasone Plus Daratumumab (SELIBORDARA) for the Treatment of Patients With Refractory or Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, single-arm, open, non-randomized, multicenter study of the SINE™ compound selinexor&#xD;
      plus low-dose dexamethasone, in combination with bortezomib and daratumumab.&#xD;
&#xD;
      100 mg selinexor (on days 1, 8, 15 and 22), plus 40 mg dexamethasone (20 mg IV the day of&#xD;
      daratumumab and selinexor and 20 mg oral administration the day after daratumumab and&#xD;
      selinexor) both weekly as continuous therapy.&#xD;
&#xD;
      Bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 once weekly on days 1, 8, 15&#xD;
      and 22 during the cycles 1 to cycle 8, and on day 1 and day 15 of each cycle thereafter as&#xD;
      continuous therapy.&#xD;
&#xD;
      Daratumumab will be given via intravenous at dose of 16 mg/Kg on days 1, 8, 15 and 22&#xD;
      (weekly) during the cycles 1 and 2, every two weeks (on days 1 and 15) during the cycles 3 to&#xD;
      6 and on day 1 of each cycle thereafter as continuous therapy.&#xD;
&#xD;
      Patients may continue indefinitely and there is no maximum treatment duration&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, single-arm, open, non-randomized, multicenter study of the SINE™ compound&#xD;
      selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab.&#xD;
&#xD;
      Sixty-two patients with R/R MM who meet eligibility criteria and have none of the exclusion&#xD;
      criteria will be enrolled to receive SVDd until either disease progression or intolerance has&#xD;
      occurred.&#xD;
&#xD;
      Enrolled patients will take a fixed milligram dose of 100 mg selinexor (on days 1, 8, 15 and&#xD;
      22), plus 40 mg dexamethasone (20 mg IV the day of daratumumab and selinexor and 20 mg oral&#xD;
      administration the day after daratumumab and selinexor) both weekly as continuous therapy.&#xD;
&#xD;
      Bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 once weekly on days 1, 8, 15&#xD;
      and 22 during the cycles 1 to cycle 8, and on day 1 and day 15 of each cycle thereafter as&#xD;
      continuous therapy.&#xD;
&#xD;
      Daratumumab will be given via intravenous at dose of 16 mg/Kg on days 1, 8, 15 and 22&#xD;
      (weekly) during the cycles 1 and 2, every two weeks (on days 1 and 15) during the cycles 3 to&#xD;
      6 and on day 1 of each cycle thereafter as continuous therapy.&#xD;
&#xD;
      Patients may continue indefinitely and there is no maximum treatment duration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an investigator-sponsored, open-label, non-randomized Phase 2 study to evaluate the efficacy and safety of this combination for a total of 62 patients with refractory or relapsed/refractory MM patients. The treatment will be given until progression of the disease or inacceptable toxicity. This trial will be conducted in approximately 15-centers in Spain</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of responses type to treatment</measure>
    <time_frame>1 year</time_frame>
    <description>Note overall response rate (ORR), including stringent complete responses, complete responses (CR), very good partial responses (VGPR), and partial responses (PR) according to the International Myeloma Working Group Criteria (IMWG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Note incidence of clinical and laboratory toxicities.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Selinexor, Daratumumab, Bortezomib and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle</description>
    <arm_group_label>Selinexor, Daratumumab, Bortezomib and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter</description>
    <arm_group_label>Selinexor, Daratumumab, Bortezomib and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9</description>
    <arm_group_label>Selinexor, Daratumumab, Bortezomib and dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered</description>
    <arm_group_label>Selinexor, Daratumumab, Bortezomib and dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is, in the investigator's opinion, willing and able to comply with the&#xD;
             protocol requirements.&#xD;
&#xD;
          -  Patient has given voluntary written informed consent before performance of any&#xD;
             study-related procedure not part of normal medical care, with the understanding that&#xD;
             consent may be withdrawn by the patient at any time without prejudice to their future&#xD;
             medical care.&#xD;
&#xD;
          -  Patient must be at least 18 years of age.&#xD;
&#xD;
          -  Patient must have a confirmed diagnosis of symptomatic multiple myeloma and measurable&#xD;
             secretory disease, defined as either serum monoclonal protein ≥ 0,5 g/dL or urine&#xD;
             monoclonal (light chain) protein ≥ 200 mg/24 hours. For patients in whom measurable&#xD;
             disease is performed by serum FLC, the involved FLC should be ≥ 10 mg/dL, with an&#xD;
             abnormal serum FLC ratio.&#xD;
&#xD;
          -  Patients must have an ECOG performance status of 0, 1 or 2.&#xD;
&#xD;
          -  All patients must have received prior treatment with proteasome inhibitors and&#xD;
             immunomodulators: A minimum of 2 consecutive cycles of proteasome inhibitors and&#xD;
             immunomodulators are required.&#xD;
&#xD;
          -  Patients must have received ≥ 3 prior lines of therapy and be refractory to the last&#xD;
             line of therapy, or be double refractory to proteasome inhibitors and immunomodulatory&#xD;
             drugs on their most recent therapy, regardless of the prior number lines of therapy;&#xD;
             or patients were thought to be refractory if they had progressed on or within 60 days&#xD;
             of treatment with bortezomib and/or lenalidomide.&#xD;
&#xD;
          -  Patient has the following laboratory values within 14 days before Baseline visit (Day&#xD;
             1 of Cycle 1, before study drug administration): Platelet count ≥ 75 x109/L,&#xD;
             hemoglobin ≥ 8.0g/dl and absolute neutrophil count (ANC) ≥ 1.5 x 109/L; lower values&#xD;
             may be accepted if clearly are due to bone marrow involvement by multiple myeloma (ANC&#xD;
             ≥ 1.0 x 109/L and platelets ≥ 50 x109/L if bone marrow infiltration &gt; 60%). Patients&#xD;
             receiving hematopoietic growth factor support, including erythropoietin (EPO),&#xD;
             darbepoetin, granulocyte-colony stimulating factor (G-CSF) may continue to do so.&#xD;
&#xD;
          -  Corrected serum calcium &lt; 14mg/dl.&#xD;
&#xD;
          -  Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal, alanine transaminase&#xD;
             (ALT): ≤ 2.5 x the upper limit of normal, and total bilirrubin: ≤ 2.0 x the upper&#xD;
             limit of normal.&#xD;
&#xD;
          -  Calculated creatinine clearance ≥ 20 ml per minute, calculated using the formula of&#xD;
             Cockroft and Gault:Multiply times 0.85 if the patient is female, or CrCl &gt;20 mL/min as&#xD;
             measured by 24-hour urine collection&#xD;
&#xD;
          -  Women of childbearing potential must be practicing a highly effective method of birth&#xD;
             control consistent with local regulations regarding the use of birth control methods&#xD;
             for subjects participating in clinical studies: eg, established use of oral, injected&#xD;
             or implanted hormonal methods of contraception; placement of an intrauterine device or&#xD;
             intrauterine system; barrier methods: condom with spermicidal&#xD;
             foam/gel/film/cream/suppository; male partner steritilization (the vasectomized&#xD;
             partner should be the sole partner for that subject); true abstinence (when this is in&#xD;
             line with the preferred and usual lifestyle of the subject) during and after the study&#xD;
             (6 months after the last dose of any component of the treatment regimen).&#xD;
&#xD;
          -  A woman of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening within 10-14 days and 24 hours before commencing treatment. Females of&#xD;
             reproductive potential must commit either to abstain continuously from heterosexual&#xD;
             sexual intercourse or to use two methods or reliable birth control simultaneously&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has received selinexor or daratumumab therapies previously.&#xD;
&#xD;
          -  Patients who are refractory to daratumumab or CD38 targeting antibody.&#xD;
&#xD;
          -  Subject has a diagnosis of plasma cell leukemia, primary amyloidosis, monoclonal&#xD;
             gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM).&#xD;
&#xD;
          -  Subject has previously received autologous stem cell transplantation within 12 weeks&#xD;
             before Cycle Day 1, or has received other anti-myeloma treatment within 2 weeks before&#xD;
             Cycle 1 Day 1 (with the exception of an emergency use of a short course [maximum 4&#xD;
             days] of corticosteroids [40 mg/day dexamethasone or equivalent]).&#xD;
&#xD;
          -  Subject who had previously received allogeneic stem cell transplantation within the&#xD;
             last year or even latter if they have evidence of graft versus host disease.&#xD;
&#xD;
          -  Subject has peripheral neuropathy or neuropathic pain grade 2 or higher, as defined by&#xD;
             the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI&#xD;
             CTCAE) Version 4.&#xD;
&#xD;
          -  Subject has had any prior or concurrent invasive malignancy (other than myeloma)&#xD;
             within 5 years of study start except adequately treated basal cell or squamous cell&#xD;
             carcinoma of the skin, carcinoma in situ of the cervix, localized prostate&#xD;
             adenocarcinoma diagnosed ≥ 3 years and without evidence of biochemical failure, or&#xD;
             other cancer for which the subject has undergone potentially curative therapy and has&#xD;
             no evidence of that disease for ≥ 5 years.&#xD;
&#xD;
          -  Subject has had radiation therapy within 28 days of Cycle 1 Day 1.&#xD;
&#xD;
          -  Subject has meningeal involvement of multiple myeloma.&#xD;
&#xD;
          -  Subject has known severe chronic obstructive pulmonary disease (COPD) (defined as a&#xD;
             forced expiratory volume [FEV] in 1 second &lt;60% of predicted normal), persistent&#xD;
             asthma, or a history of severe asthma within 5 years. Subjects with known or suspected&#xD;
             COPD or asthma must have a FEV test during screening.&#xD;
&#xD;
          -  Subjects have known moderate or severe persistent asthma within the past 2 years (see&#xD;
             Appendix 8: National Heart, Lung, and Blood Institute (NHLBI) table of asthma&#xD;
             severity), or currently has uncontrolled asthma of any classification. (Note that&#xD;
             subjects who currently have controlled intermittent asthma or controlled mild&#xD;
             ersistene asthma are allowed in the study).&#xD;
&#xD;
          -  Unstable cardiovascular function:Symptomatic ischemia, or Uncontrolled&#xD;
             clinically-significant conduction abnormalities (e.g., patients with ventricular&#xD;
             tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular&#xD;
             (AV) block or asymptomatic left anterior fascicular block/right bundle branch block&#xD;
             (LAFB/RBBB) will not be excluded), or Congestive heart failure (CHF) of New York Heart&#xD;
             Association (NYHA) Class ≥ 3, or Myocardial infarction (MI) within 3 months.&#xD;
&#xD;
          -  Patients with uncontrolled hypertension.&#xD;
&#xD;
          -  Uncontrolled active infection requiring parenteral antibiotics, antivirals, or&#xD;
             antifungals within one week prior to first dose.&#xD;
&#xD;
          -  Subject is known to be seropositive for history of human immunodeficiency virus (HIV)&#xD;
             or hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or&#xD;
             antibodies to hepatitis B surface and core antigens [anti HBs and anti-HBc,&#xD;
             respectively]) or hepatitis C (anti-HCV antibody positive or HCV-RNA quantitation&#xD;
             positive).&#xD;
&#xD;
          -  Patients with any GI dysfunction who are unable to swallow tablets, or any GI&#xD;
             dysfunction that could interfere with absorption of study treatment&#xD;
&#xD;
          -  Serious psychiatric or medical conditions that, in the opinion of the investigator,&#xD;
             could interfere with treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jesús San Miguel, Prof</last_name>
    <phone>+34 948 255 400</phone>
    <email>sanmiguel@unav.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mª Victoria Mateos, Dr</last_name>
    <phone>+ 34 923 291384</phone>
    <email>mateos@usal.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Germans Trials i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Oriol, Dr</last_name>
      <email>aoriol@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Bladé, Dr</last_name>
      <email>JBLADE@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital ICO de Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Gonzalez, Dr</last_name>
      <email>ygonzalez@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital ICO de L'hospitalet</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sureda, Dr</last_name>
      <email>asureda@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan José Lahuerta, Dr</last_name>
      <email>JJLAHUERTA@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Martinez, Dr</last_name>
      <email>rafaelbenigno.martinez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe de Arriba, Dr</last_name>
      <email>farriba@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Pilar Gonzalez, Dr</last_name>
      <email>anapilargonzalez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús San Miguel, Prof</last_name>
      <email>sanmiguel@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Victoria Mateos, Dr</last_name>
      <email>mateos@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maialen Sirvent, Dr</last_name>
      <email>MAIALEN.SIRVENTAUZMENDI@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Sonia Gonzalez, Dr</last_name>
      <email>marta.sonia.gonzalez.perez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Martín, Dr</last_name>
      <email>jesus.martin.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Hernandez, Dr</last_name>
      <email>mthernan@ull.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de la Rubia, Dr</last_name>
      <email>delarubia_jav@gva.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

